FGFR2 fusion mutations are reported in 13–20% of patients with intrahepatic cholangiocarcinoma (Harimoto et al., 2010; Chen et al., 2013; Jun et al., 2020). Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.